

Qinglong Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/79044/publications.pdf>

Version: 2024-02-01

133
papers

4,233
citations

101543

36
h-index

168389

53
g-index

145
all docs

145
docs citations

145
times ranked

5091
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-hepatitis B virus activity of wogonin in vitro and in vivo. <i>Antiviral Research</i> , 2007, 74, 16-24.	4.1	158
2	Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF- κ B and NLRP3 inflammasome activation. <i>Biochemical Pharmacology</i> , 2015, 94, 142-154.	4.4	134
3	Wogonin induced G1 cell cycle arrest by regulating Wnt/ β -catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. <i>Toxicology</i> , 2013, 312, 36-47.	4.2	92
4	Glycyrrhetic Acid Functionalized Graphene Oxide for Mitochondria Targeting and Cancer Treatment In Vivo. <i>Small</i> , 2018, 14, 1703306.	10.0	89
5	Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. <i>Blood</i> , 2013, 121, 3682-3691.	1.4	85
6	Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3298-3305.	4.1	84
7	Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway. <i>Biochemical Pharmacology</i> , 2014, 92, 220-234.	4.4	76
8	Overview of Oroxylin A: A Promising Flavonoid Compound. <i>Phytotherapy Research</i> , 2016, 30, 1765-1774.	5.8	74
9	Beclin 1-mediated autophagy in hepatocellular carcinoma cells: Implication in anticancer efficiency of oroxylin A via inhibition of mTOR signaling. <i>Cellular Signalling</i> , 2012, 24, 1722-1732.	3.6	70
10	Oroxylin A suppresses the development and growth of colorectal cancer through reprogram of HIF1 α -modulated fatty acid metabolism. <i>Cell Death and Disease</i> , 2017, 8, e2865-e2865.	6.3	67
11	Artemisinin derivatives inactivate cancer-associated fibroblasts through suppressing TGF- β 2 signaling in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 282.	8.6	67
12	Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. <i>European Journal of Pharmacology</i> , 2009, 603, 22-28.	3.5	65
13	Wogonin inhibits tumor angiogenesis via degradation of HIF-1 α protein. <i>Toxicology and Applied Pharmacology</i> , 2013, 271, 144-155.	2.8	64
14	Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF- κ B pathway through PPAR γ 3 activation. <i>Biochemical Pharmacology</i> , 2016, 106, 70-81.	4.4	59
15	Toxicological Studies of Gambogic Acid and its Potential Targets in Experimental Animals. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2006, 99, 178-184.	2.5	57
16	Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction. <i>Toxicology</i> , 2009, 259, 10-17.	4.2	57
17	Gambogic acid inhibits tumor cell adhesion by suppressing integrin β 1 and membrane lipid rafts-associated integrin signaling pathway. <i>Biochemical Pharmacology</i> , 2011, 82, 1873-1883.	4.4	57
18	Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. <i>Toxicology Letters</i> , 2012, 209, 211-220.	0.8	57

#	ARTICLE	IF	CITATIONS
19	Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression. <i>Cell Death and Disease</i> , 2017, 8, e2944-e2944.	6.3	57
20	Inhibitory effects of wogonin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9. <i>Toxicology</i> , 2011, 282, 122-128.	4.2	56
21	Gambogic acid promotes apoptosis and resistance to metastatic potential in MDA-MB-231 human breast carcinoma cells. <i>Biochemistry and Cell Biology</i> , 2012, 90, 718-730.	2.0	56
22	LFG-500, a newly synthesized flavonoid, attenuates lipopolysaccharide-induced acute lung injury and inflammation in mice. <i>Biochemical Pharmacology</i> , 2016, 113, 57-69.	4.4	56
23	Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721. <i>Anti-Cancer Drugs</i> , 2006, 17, 797-805.	1.4	55
24	Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. <i>Molecular Carcinogenesis</i> , 2009, 48, 1159-1169.	2.7	53
25	Small molecule GL-V9 protects against colitis-associated colorectal cancer by limiting NLRP3 inflammasome through autophagy. <i>Oncotarget</i> , 2018, 7, e1375640.	4.6	50
26	Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF- κ B signaling. <i>European Journal of Pharmacology</i> , 2014, 737, 57-69.	3.5	49
27	Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells. <i>Journal of Hematology and Oncology</i> , 2015, 8, 41.	17.0	47
28	Flavonoid VI-16 protects against DSS-induced colitis by inhibiting Txnip-dependent NLRP3 inflammasome activation in macrophages via reducing oxidative stress. <i>Mucosal Immunology</i> , 2019, 12, 1150-1163.	6.0	47
29	Overview of AKR1C3: Inhibitor Achievements and Disease Insights. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 11305-11329.	6.4	47
30	Wogonoside prevents colitis-associated colorectal carcinogenesis and colon cancer progression in inflammation-related microenvironment via inhibiting NF- κ B activation through PI3K/Akt pathway. <i>Oncotarget</i> , 2016, 7, 34300-34315.	1.8	42
31	Oroxylin A prevents angiogenesis of LSECs in liver fibrosis via inhibition of YAP/HIF-1 α signaling. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 2258-2268.	2.6	41
32	Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2013, 1830, 3835-3845.	2.4	39
33	CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells. <i>Biochemical Pharmacology</i> , 2014, 90, 212-225.	4.4	39
34	Wogonoside inhibits invasion and migration through suppressing TRAF2/4 expression in breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 103.	8.6	39
35	Different apoptotic effects of wogonin via induction of H ₂ O ₂ generation and Ca ²⁺ overload in malignant hepatoma and normal hepatic cells. <i>Journal of Cellular Biochemistry</i> , 2010, 111, 1629-1641.	2.6	38
36	Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest. <i>Toxicology Letters</i> , 2013, 219, 107-115.	0.8	38

#	ARTICLE	IF	CITATIONS
37	Wogonoside inhibits angiogenesis in breast cancer via suppressing Wnt/ β -catenin pathway. <i>Molecular Carcinogenesis</i> , 2016, 55, 1598-1612.	2.7	38
38	Small molecule modulators targeting protein kinase CK1 and CK2. <i>European Journal of Medicinal Chemistry</i> , 2019, 181, 111581.	5.5	38
39	Wogonin induces cellular senescence in breast cancer via suppressing TXNRD2 expression. <i>Archives of Toxicology</i> , 2020, 94, 3433-3447.	4.2	38
40	UCP2-Related Mitochondrial Pathway Participates in Oroxylin A-Induced Apoptosis in Human Colon Cancer Cells. <i>Journal of Cellular Physiology</i> , 2015, 230, 1054-1063.	4.1	37
41	Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 667-675.	2.5	36
42	Wogonin inhibits H ₂ O ₂ -induced angiogenesis via suppressing PI3K/Akt/NF- κ B signaling pathway. <i>Vascular Pharmacology</i> , 2014, 60, 110-119.	2.1	36
43	Regulation of AMPK-related glycolipid metabolism imbalances redox homeostasis and inhibits anchorage independent growth in human breast cancer cells. <i>Redox Biology</i> , 2018, 17, 180-191.	9.0	36
44	Inhibitory effects of GL-V9 on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 43, 393-399.	4.0	35
45	Two p53-related metabolic regulators, TIGAR and SCO2, contribute to oroxylin A-mediated glucose metabolism in human hepatoma HepG2 cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1468-1478.	2.8	35
46	The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP, and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis. <i>Free Radical Biology and Medicine</i> , 2015, 82, 29-41.	2.9	35
47	Selective anti-tumor activity of wogonin targeting the Warburg effect through stabilizing p53. <i>Pharmacological Research</i> , 2018, 135, 49-59.	7.1	35
48	Wogonin induced cytotoxicity in human hepatocellular carcinoma cells by activation of unfolded protein response and inactivation of AKT. <i>Hepatology Research</i> , 2013, 43, 890-905.	3.4	34
49	Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells. <i>Oncotarget</i> , 2014, 5, 8188-8201.	1.8	34
50	Oroxylin A Inhibits Colitis-associated Carcinogenesis Through Modulating the IL-6/STAT3 Signaling Pathway. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	33
51	LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer. <i>Carcinogenesis</i> , 2018, 39, 588-600.	2.8	33
52	Design, synthesis, biological evaluation, and molecular modeling studies of quinoline-ferulic acid hybrids as cholinesterase inhibitors. <i>Bioorganic Chemistry</i> , 2019, 93, 103310.	4.1	33
53	GL-V9, a new synthetic flavonoid derivative, ameliorates DSS-induced colitis against oxidative stress by up-regulating Trx-1 expression via activation of AMPK/FOXO3a pathway. <i>Oncotarget</i> , 2015, 6, 26291-26307.	1.8	32
54	Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3 β signaling in snail-expressing non-small cell lung cancer cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 2121-2134.	2.7	32

#	ARTICLE	IF	CITATIONS
55	GL-V9, a newly synthetic flavonoid derivative, induces mitochondrial-mediated apoptosis and G2/M cell cycle arrest in human hepatocellular carcinoma HepG2 cells. <i>European Journal of Pharmacology</i> , 2011, 670, 13-21.	3.5	31
56	V8, a newly synthetic flavonoid, induces apoptosis through ROS-mediated ER stress pathway in hepatocellular carcinoma. <i>Archives of Toxicology</i> , 2014, 88, 97-107.	4.2	31
57	Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF- κ B inactivation. <i>Scientific Reports</i> , 2017, 7, 39950.	3.3	31
58	LZ-106, a novel analog of enoxacin, inducing apoptosis via activation of ROS-dependent DNA damage response in NSCLCs. <i>Free Radical Biology and Medicine</i> , 2016, 95, 155-168.	2.9	30
59	Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1 α mediated XPC transcription. <i>Oncogene</i> , 2020, 39, 6893-6905.	5.9	30
60	Gambogic acid suppresses cancer invasion and migration by inhibiting TGF β 1-induced epithelial-to-mesenchymal transition. <i>Oncotarget</i> , 2017, 8, 27120-27136.	1.8	29
61	Activation of the unfolded protein response contributed to the selective cytotoxicity of oroxylin A in human hepatocellular carcinoma HepG2 cells. <i>Toxicology Letters</i> , 2012, 212, 113-125.	0.8	28
62	Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPAR β and RXR α . <i>International Journal of Cancer</i> , 2014, 134, 1195-1206.	5.1	28
63	Oroxylin A reverses CAM-DR of HepG2 cells by suppressing Integrin β 1 and its related pathway. <i>Toxicology and Applied Pharmacology</i> , 2012, 259, 387-394.	2.8	27
64	LFG-500 Inhibits the Invasion of Cancer Cells via Down-Regulation of PI3K/AKT/NF- κ B Signaling Pathway. <i>PLoS ONE</i> , 2014, 9, e91332.	2.5	27
65	Reasonably activating Nrf2: A long-term, effective and controllable strategy for neurodegenerative diseases. <i>European Journal of Medicinal Chemistry</i> , 2020, 185, 111862.	5.5	27
66	GSK3 β / β -catenin signaling is correlated with the differentiation of glioma cells induced by wogonin. <i>Toxicology Letters</i> , 2013, 222, 212-223.	0.8	26
67	LW-214, a newly synthesized flavonoid, induces intrinsic apoptosis pathway by down-regulating Trx-1 in MCF-7 human breast cells. <i>Biochemical Pharmacology</i> , 2014, 87, 598-610.	4.4	26
68	LZ205, a newly synthesized flavonoid compound, exerts anti-inflammatory effect by inhibiting M1 macrophage polarization through regulating PI3K/AKT/mTOR signaling pathway. <i>Experimental Cell Research</i> , 2018, 364, 84-94.	2.6	26
69	VI-14, a novel flavonoid derivative, inhibits migration and invasion of human breast cancer cells. <i>Toxicology and Applied Pharmacology</i> , 2012, 261, 217-226.	2.8	24
70	FV-429 induces apoptosis and inhibits glycolysis by inhibiting Akt-mediated phosphorylation of hexokinase II in MDA-MB-231 cells. <i>Molecular Carcinogenesis</i> , 2016, 55, 1317-1328.	2.7	24
71	Oroxylin A prevents alcohol-induced hepatic steatosis through inhibition of hypoxia inducible factor 1 α . <i>Chemico-Biological Interactions</i> , 2018, 285, 14-20.	4.0	24
72	YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15184-15193.	7.1	24

#	ARTICLE	IF	CITATIONS
73	Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation. <i>Bioorganic Chemistry</i> , 2019, 85, 117-127.	4.1	24
74	Triggering apoptosis by oroxylin A through caspase-8 activation and p62/SQSTM1 proteolysis. <i>Redox Biology</i> , 2020, 29, 101392.	9.0	24
75	Oroxylin A suppresses ACTN1 expression to inactivate cancer-associated fibroblasts and restrain breast cancer metastasis. <i>Pharmacological Research</i> , 2020, 159, 104981.	7.1	24
76	Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide. <i>Pharmacological Reports</i> , 2012, 64, 1189-1199.	3.3	23
77	Effect of magnetic nanoparticles of Fe ₃ O ₄ and wogonin on the reversal of multidrug resistance in K562/A02 cell line. <i>International Journal of Nanomedicine</i> , 2012, 7, 2843.	6.7	23
78	Role of Gut Microbiota in the Pharmacological Effects of Natural Products. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-7.	1.2	23
79	Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429. <i>Cell Death and Disease</i> , 2018, 8, e3178-e3178.	6.3	22
80	Natural HDAC inhibitor baicalein exerts therapeutic effect in CBF-AML. <i>Clinical and Translational Medicine</i> , 2020, 10, e154.	4.0	22
81	Kinesin spindle protein Inhibitors as anticancer agents. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1517-1532.	5.0	21
82	Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment. <i>Molecular Carcinogenesis</i> , 2017, 56, 863-876.	2.7	21
83	Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1 α /hedgehog pathway under hypoxia. <i>Journal of Cellular Physiology</i> , 2019, 234, 17392-17404.	4.1	21
84	E platinum, a newly synthesized platinum compound, induces apoptosis through ROS-triggered ER stress in gastric carcinoma cells. <i>Molecular Carcinogenesis</i> , 2017, 56, 218-231.	2.7	20
85	Oroxylin A induces apoptosis of activated hepatic stellate cells through endoplasmic reticulum stress. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2019, 24, 905-920.	4.9	20
86	Oroxylin A modulates mitochondrial function and apoptosis in human colon cancer cells by inducing mitochondrial translocation of wild-type p53. <i>Oncotarget</i> , 2016, 7, 17009-17020.	1.8	19
87	GL-V9 induced upregulation and mitochondrial localization of NAG-1 associates with ROS generation and cell death in hepatocellular carcinoma cells. <i>Free Radical Biology and Medicine</i> , 2017, 112, 49-59.	2.9	19
88	LW-215, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo. <i>Gene</i> , 2018, 642, 533-541.	2.2	19
89	LYG-202, a Newly Synthesized Flavonoid, Exhibits Potent Anti-angiogenic Activity In Vitro and In Vivo. <i>Journal of Pharmacological Sciences</i> , 2010, 112, 37-45.	2.5	18
90	LYG-202 exerts antitumor effect on PI3K/Akt signaling pathway in human breast cancer cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015, 20, 1253-1269.	4.9	18

#	ARTICLE	IF	CITATIONS
91	PLSCR1/IP3R1/Ca ²⁺ axis contributes to differentiation of primary AML cells induced by wogonoside. <i>Cell Death and Disease</i> , 2017, 8, e2768-e2768.	6.3	18
92	Wogonin inhibits H ₂ O ₂ -induced vascular permeability through suppressing the phosphorylation of caveolin-1. <i>Toxicology</i> , 2013, 305, 10-19.	4.2	17
93	FV-429 Induced Apoptosis Through ROS-Mediated ERK2 Nuclear Translocation and p53 Activation in Gastric Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1624-1637.	2.6	17
94	LL202 protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting MAPK/AP-1 signaling. <i>Oncotarget</i> , 2016, 7, 63981-63994.	1.8	17
95	Oroxyloside inhibits angiogenesis through suppressing internalization of VEGFR2/Flk-1 in endothelial cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 3454-3464.	4.1	17
96	Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. <i>Journal of Cellular Physiology</i> , 2019, 234, 1913-1924.	4.1	17
97	Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells. <i>Archives of Toxicology</i> , 2016, 90, 1507-1522.	4.2	16
98	Wogonin influences vascular permeability via Wnt/ β -catenin pathway. <i>Molecular Carcinogenesis</i> , 2015, 54, 501-512.	2.7	15
99	Involvement of p53 Acetylation in Growth Suppression of Cutaneous T-Cell Lymphomas Induced by HDAC Inhibition. <i>Journal of Investigative Dermatology</i> , 2020, 140, 2009-2022.e4.	0.7	15
100	FV-429 induces autophagy blockage and lysosome-dependent cell death of T-cell malignancies via lysosomal dysregulation. <i>Cell Death and Disease</i> , 2021, 12, 80.	6.3	15
101	LYG-202 inhibits the proliferation of human colorectal carcinoma HCT-116 cells through induction of G1/S cell cycle arrest and apoptosis via p53 and p21 ^{WAF1/Cip1} expression. <i>Biochemistry and Cell Biology</i> , 2011, 89, 287-298.	2.0	14
102	Oroxylin A inhibits hypoxia-induced invasion and migration of MCF-7 cells by suppressing the Notch pathway. <i>Anti-Cancer Drugs</i> , 2014, 25, 778-789.	1.4	14
103	Oroxyloside ameliorates acetaminophen-induced hepatotoxicity by inhibiting JNK related apoptosis and necroptosis. <i>Journal of Ethnopharmacology</i> , 2020, 258, 112917.	4.1	14
104	LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia. <i>Theranostics</i> , 2021, 11, 93-106.	10.0	13
105	Oroxylin A, a natural anticancer flavonoid compound, induces differentiation of t(8;21)-positive Kasumi-1 and primary acute myeloid leukemia cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1449-1459.	2.5	12
106	Oroxylin A, a natural compound, mitigates the negative effects of TNF α -treated acute myelogenous leukemia cells. <i>Carcinogenesis</i> , 2018, 39, 1292-1303.	2.8	12
107	Mitotic catastrophe and p53-dependent senescence induction in T-cell malignancies exposed to nonlethal dosage of GL-V9. <i>Archives of Toxicology</i> , 2020, 94, 305-323.	4.2	12
108	The Synthetic Flavonoid Derivative GL-V9 Induces Apoptosis and Autophagy in Cutaneous Squamous Cell Carcinoma via Suppressing AKT-Regulated HK2 and mTOR Signals. <i>Molecules</i> , 2020, 25, 5033.	3.8	12

#	ARTICLE	IF	CITATIONS
109	Cholesterol-associated lysosomal disorder triggers cell death of hematological malignancy: Dynamic analysis on cytotoxic effects of LW-218. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3178-3192.	12.0	12
110	Activation of endoplasmic reticulum stress and the extrinsic apoptotic pathway in human lung cancer cells by the new synthetic flavonoid, LZ-205. <i>Oncotarget</i> , 2016, 7, 87257-87270.	1.8	11
111	Glucocorticoid receptor dysfunction orchestrates inflammasome effects on chronic obstructive pulmonary disease-induced depression: A potential mechanism underlying the cross talk between lung and brain. <i>Brain, Behavior, and Immunity</i> , 2019, 79, 195-206.	4.1	11
112	AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma. <i>Oncogene</i> , 2022, 41, 3846-3858.	5.9	11
113	Design and synthesis of novel 4- β -demethyl-4-deoxypodophyllotoxin derivatives as potential anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1360-1364.	2.2	9
114	Activation of phospholipase C- β 1 and translocation of phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase contribute to GL-V9-induced apoptosis in human gastric cancer cells. <i>Experimental Cell Research</i> , 2017, 356, 8-19.	2.6	9
115	Wogonoside induces depalmitoylation and translocation of PLSCR1 and RAS in primary acute myeloid leukaemia cells. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2117-2130.	3.6	9
116	G1 phase cell cycle arrest in NSCLC in response to LZ-106, an analog of enoxacin, is orchestrated through ROS overproduction in a P53-dependent manner. <i>Carcinogenesis</i> , 2019, 40, 131-144.	2.8	9
117	Oroxylin A inhibits ATRA-induced IL-6 expression involved in retinoic acid syndrome by down-regulating CHOP. <i>Gene</i> , 2014, 551, 230-235.	2.2	8
118	Wogonin inhibits LPS-induced vascular permeability via suppressing MLCK/MLC pathway. <i>Vascular Pharmacology</i> , 2015, 72, 43-52.	2.1	8
119	One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-20.	4.0	8
120	Oroxylin A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway. <i>Frontiers in Pharmacology</i> , 2017, 8, 526.	3.5	7
121	GL-V9 exerts anti-T cell malignancies effects via promoting lysosome-dependent AKT1 degradation and activating AKT1/FOXO3A/BIM axis. <i>Free Radical Biology and Medicine</i> , 2019, 145, 237-249.	2.9	7
122	Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment. <i>Annals of Translational Medicine</i> , 2020, 8, 1046-1046.	1.7	7
123	Glycolysis inhibition and apoptosis induction in human prostate cancer cells by FV-429-mediated regulation of AR-AKT-HK2 signaling network. <i>Food and Chemical Toxicology</i> , 2020, 143, 111517.	3.6	7
124	Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 1286-1294.	2.8	7
125	LZ-207, a Newly Synthesized Flavonoid, Induces Apoptosis and Suppresses Inflammation-Related Colon Cancer by Inhibiting the NF- κ B Signaling Pathway. <i>PLoS ONE</i> , 2015, 10, e0127282.	2.5	6
126	LFG-500, a newly synthesized flavonoid, induces apoptosis in human ovarian carcinoma SKOV3 cells with involvement of the reactive oxygen species-mitochondria pathway. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 2819-2827.	1.8	6

#	ARTICLE	IF	CITATIONS
127	<i>In silico</i> approaches using pharmacophore model combined with molecular docking for discovery of novel ULK1 inhibitors. <i>Future Medicinal Chemistry</i> , 2021, 13, 341-361.	2.3	6
128	LL202 inhibits lipopolysaccharide-induced angiogenesis in vivo and in vitro. <i>RSC Advances</i> , 2014, 4, 64565-64576.	3.6	5
129	AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p. <i>Cellular Signalling</i> , 2021, 84, 110038.	3.6	5
130	Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia. <i>Cell Communication and Signaling</i> , 2021, 19, 83.	6.5	5
131	Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors. <i>Chemico-Biological Interactions</i> , 2022, 351, 109746.	4.0	5
132	The involvement of lipid raft pathway in suppression of TGF β 2-mediated metastasis by tolfenamic acid in hepatocellular carcinoma cells. <i>Toxicology and Applied Pharmacology</i> , 2019, 380, 114696.	2.8	3
133	LZ-106, a potent lysosomotropic agent, causing TFEB-dependent cytoplasmic vacuolization. <i>Gene</i> , 2020, 760, 145017.	2.2	1